OneSource Specialty Pharma Ltd.

OneSource-Hikma get Saudi FDA nod for generic Ozempic (semaglutide). Partnership aims to scale access in MENA region. Details here.

TPG, a private equity giant, sold 8.84 lakh shares of Onesource Specialty Pharma for Rs 139 crore through an open market transaction. Learn more about the deal and its implications.

OneSource Specialty Pharma's Unit 2 in Bengaluru receives GMP certification from ANVISA, enabling the company to supply pharmaceutical products, including GLP-1s, to the Brazilian market.

Three entities, including promoters of Onesource Specialty Pharma, divested a 6.8% stake for Rs 1,202 crore through open market transactions. Motilal Oswal Mutual Fund and CPT Research & Mgmt Co...

Strides Pharma Science's CDMO arm, OneSource Specialty Pharma, secures Rs 801 crore in pre-listing funding from investors, aiming to accelerate growth and expand operations.

Reliance Industries shares fell over 1% ahead of Q4 earnings. Market valuation at Rs 18,01,248.57 crore. Sensex and Nifty also declined.

Infosys board approves Rs 51.75 crore stock grants for CEO Salil Parekh. Details on performance-based RSUs, ESG-linked grants, and TSR grants.

DCB Bank reports a 16% rise in Q4 net profit to Rs 206 crore. Gross NPA moderates. Board approves raising up to Rs 2,000 crore.

FY26 highway construction falls short of target due to land acquisition delays. Slowdown attributed to fewer new projects awarded.

Anthropic's Mythos AI model sparks global alarm over financial system vulnerabilities. Banks review defenses against potential cyber attacks.

Reliance Industries shares fell over 1% ahead of Q4 earnings. Market valuation at Rs 18,01,248.57 crore. Sensex and Nifty also declined.

Today's areca and coconut prices in Mangaluru. Get the latest rates for old supari, new supari, koka, 1st quality coconut, and 2nd quality coconut.

Infosys board approves Rs 51.75 crore stock grants for CEO Salil Parekh. Details on performance-based RSUs, ESG-linked grants, and TSR grants.

DCB Bank reports a 16% rise in Q4 net profit to Rs 206 crore. Gross NPA moderates. Board approves raising up to Rs 2,000 crore.

FY26 highway construction falls short of target due to land acquisition delays. Slowdown attributed to fewer new projects awarded.